微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 66.95% | 2.02% | 7.43% | 38/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 62.32% | 0.37% | 0.67% | 45/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 61.91% | 1.28% | 1.34% | 45/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 61.09% | -0.23% | -6.92% | 48/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 65.63% | 10.01% | 5.7% | 35/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 62.09% | 8.16% | 1.58% | 47/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 61.12% | 4.57% | -0.17% | 49/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 61.23% | 5.87% | 2.63% | 49/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 59.66% | 3.11% | 3.92% | 52/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 57.41% | -2.44% | -1.78% | 63/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 58.45% | 0.71% | 1.06% | 61/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 57.83% | -0.77% | -0.05% | 60/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 57.86% | 1.36% | -1.67% | 59/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 58.84% | -6.08% | 1.39% | 59/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 58.04% | -6.68% | -0.42% | 61/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 58.28% | -8.16% | 2.1% | 62/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 57.08% | -12.18% | -8.89% | 64/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 62.65% | -5.31% | 0.75% | 59/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 62.19% | -5.26% | -2% | 49/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 63.46% | -0.94% | -2.37% | 51/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 65% | 0.48% | -1.76% | 38/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 66.17% | -14.61% | 0.8% | 46/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 65.64% | -16.46% | 2.46% | 39/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 64.06% | -19.1% | -0.96% | 43/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 64.69% | -18.81% | -16.52% | 37/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 77.49% | -7.32% | -1.38% | 24/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 78.57% | -6.57% | -0.78% | 15/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 79.19% | -8.37% | -0.62% | 18/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 79.68% | -6.81% | -4.7% | 13/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 83.61% | -3.87% | -0.58% | 18/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 84.09% | -3.24% | -2.69% | 11/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 86.42% | -2.41% | 1.08% | 8/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 85.5% | -3.87% | -1.7% | 7/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 86.97% | 0.02% | 0.07% | 8/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 86.91% | -0.3% | -1.85% | 4/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 88.55% | 0.92% | -0.43% | 3/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 88.94% | 1.92% | 2.28% | 3/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 86.95% | -0.98% | -0.25% | 6/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 87.17% | -1.08% | -0.65% | 3/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 87.74% | -0.29% | 0.55% | 3/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 87.26% | -0.17% | -0.63% | 2/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |